PharmTech Drug Digest 11.20
News|Articles|August 29, 2013

Merck KGaA Names James Stewart CIO

Author(s)Melanie Sena

James Stewart named CIO of Merck KGaA.

Merck KGaA announced that James Stewart will become CIO of the Merck Group in October 2013. As CIO, Stewart will report to Kai Beckmann, member of Merck KGaA’s Executive Board. Stewart succeeds Frédéric Wohlwend, who has decided to pursue opportunities outside Merck.

James Stewart joined the biopharmaceutical division of Merck KGaA in 2011. Prior to joining Merck KGaA, he had a career with MSD (in the U.S.: Merck & Co.), where he started in Human Resources and progressed through several global business and functional leadership roles.

Source: Merck KGaA


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.